Perceptive Advisors LLC Akebia Therapeutics, Inc. Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $126,010 - $689,629	-52,724 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $351,669 - $715,991	52,724 New	52,724 $716,000
Q2 2019 Aug 14, 2019	SELL	$4.1 - $8.05 $6.98 Million - $13.7 Million	-1,703,440 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$5.39 - $9.15 $4.02 Million - $6.83 Million	-746,081 Reduced 30.46%	1,703,440 $9.18 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $1.74 Million - $2.49 Million	234,121 Added 10.57%	2,449,521 $21.6 Million
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $2.26 Million - $2.8 Million	-247,000 Reduced 10.03%	2,215,400 $22.1 Million
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $4.53 Million - $7.45 Million	475,000 Added 23.9%	2,462,400 $23.5 Million
Q4 2017 Feb 14, 2018	BUY	$14.24 - $19.59 $5.09 Million - $7 Million	357,400 Added 21.93%	1,987,400 $29.6 Million
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $21.3 Million - $32.1 Million	1,630,000	1,630,000 $32.1 Million

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $338M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.